Compare Dolby Laboratories, Inc. (DLB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Novartis AG — how do they compare? Dolby Laboratories, Inc. trades at $58.45 (market cap $5.47B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 50.1× Dolby Laboratories, Inc.'s market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Novartis AG for 82 Days on average.
| DLB | NVS | |
|---|---|---|
Market Cap | $5.47B | $274.00B |
Volume | 691,016 | 1,852,137 |
Sector | Technology | Health |
52-Week High | $70.09 | $168.62 |
52-Week Low | $48.51 | $121.80 |
Typical Hold Time | 98 Days | 82 Days |
Enterprise Value | $4.84B | $315.32B |
Dividend Yield | 2.47% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals despite strong profitability margins. The company maintains robust fundamentals with 87.61% gross margins and consistent earnings beats, though revenue has plateaued around $1.3B. Recent leadership transition to Marc Whitten and expanded Meta partnership for Dolby Atmos/Vision represent key developments. Technical indicators show resistance at $59 with support at $58.
DLB offers stable cash flow generation and dividend income but faces growth challenges with flat revenue. Analyst consensus targets $90.33 (55% upside) with 47% buy ratings, though near-term execution risks and licensing volatility warrant caution. The stock presents value for income investors but requires revenue acceleration for significant appreciation.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
